No Detail Found!

Comparison of deferasirox and desferrioxamine as iron chelators in multi- transfused patients of β-thalassemia major

Author(s)
AHMED A Department of Medicine, Mayo Hospital, Lahore, Pakistan
KAMRAN M Department of Medicine, Mayo Hospital, Lahore, Pakistan
MUKHTAR M Department of Pediatrics Medical Unit 1, Mayo Hospital Lahore, Pakistan
ALI M Department of Pediatrics Medical Unit 1, Mayo Hospital Lahore, Pakistan
UMAR M Department of Internal Medicine, Mayo Hospital, Lahore, Pakistan
Abstract
This study aimed to compare the efficacy of deferasirox and deferoxamine in improving hematological and immunological parameters in patients with transfusion-dependent ß-thalassemia major. 200 patients were enrolled in the study, with 100 receiving deferasirox and 100 receiving deferoxamine. The study was conducted at Mayo Hospital, Lahore. The patients were followed up for six months, during which various hematological and immunological parameters were measured at regular intervals. The data were analyzed using appropriate statistical methods. Both deferasirox and deferoxamine effectively improved hematological and immunological parameters in patients with ßthalassemia major. However, deferasirox was more effective than deferoxamine in improving hemoglobin, red blood cell count, and hematocrit levels. In contrast, there was no significant difference between the two iron chelators in their impact on white blood cell count and platelet count. Deferasirox appears to be a more effective iron chelator than deferoxamine in improving hematological parameters in patients with transfusion-dependent ß-thalassemia major.
Publication Details
Page(s) 1-5
Published Journal: Biological and Clinical Sciences Research Journal, Volume: 4, Issue: 1, Year: 2023

Request the full text from PASTIC

Keywords
Hematological parameters, immunological parameters, Transfusion-Dependent B-Thalassemia Major, Iron Chelators., Deferoxamine
0

Citations

0

Downloads

113

Views